AMAG Pharmaceuticals

What AMAG Pharmaceuticals does

AMAG Pharmaceuticals was a specialty biopharmaceutical company founded in 1981 and headquartered in Lexington, Massachusetts, focused on developing and commercializing therapeutic solutions for patients with complex, underserved conditions — primarily iron deficiency anemia and women's health/maternal health indications. Its core product was Feraheme (ferumoxytol injection), an FDA-approved intravenous iron replacement therapy indicated for adults with iron deficiency anemia and chronic kidney disease who have had an inadequate response to oral iron. The company built a portfolio through several large acquisitions, including Lumara Health (~$675M, 2014), Cord Blood Registry (~$700M, 2015), and Perosphere Pharmaceuticals (2018), and funded these moves with capital raises of $175M (2015) and $300M (2017).

AMAG's business model was based on specialty pharmaceutical product sales distributed through hospital and clinic channels for injectable therapies like Feraheme, supplemented by pharmacy distribution networks. The company employed a sales-led go-to-market motion targeting healthcare providers and hospital systems, supported by medical affairs communications and patient assistance programs. William Heiden served as CEO. The company was listed on NASDAQ as AMAG and operated with 251-500 employees. In 2020, Covis Pharma Group (backed by Cerberus Capital Management) acquired AMAG, resulting in delisting and integration into Covis's 50+ country specialty pharmaceutical platform; the combined entity was subsequently acquired by Azurity Pharmaceuticals in 2025.

Name

AMAG Pharmaceuticals

Legal name

AMAG Pharmaceuticals

Website

https://amagpharma.com

Company type

Private

Founded year

1981

Operating status

Acquired

Headcount range

251–500 employees

Short description

AMAG Pharmaceuticals was a specialty biopharmaceutical company that developed and commercialized Feraheme (ferumoxytol) and women's health therapies for patients with iron deficiency anemia and maternal health conditions, distributing through hospital and pharmacy channels before being acquired by Covis Pharma in 2020.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

akta.pro primary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Iron deficiency therapies
• Maternal health products
• Respiratory medications
• Biopharmaceutical treatments

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of specialty pharmaceutical products including Feraheme for iron deficiency anemia and other therapeutic products in the women's health and hospital-based therapeutic categories.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

AMAG Pharmaceuticals developed and commercialized specialty pharmaceutical products for patients with complex, underserved conditions. Its portfolio centered on Feraheme (ferumoxytol injection), an intravenous iron therapy for iron deficiency anemia, alongside respiratory and maternal health products including Alvesco, Duaklir, and Tudorza.

Product overview

AMAG Pharmaceuticals was a specialty pharmaceutical company focused on maternal health and iron deficiency therapies. The company operated as a single-product-focused business with Feraheme (ferumoxytol) as its primary product for treating iron deficiency anemia. In 2020, Covis Pharma Group acquired AMAG Pharmaceuticals, integrating Feraheme into its broader global specialty pharmaceutical portfolio. The combined entity markets therapeutic solutions in 50+ countries for patients with life-threatening conditions and chronic illnesses, including respiratory therapies (Alvesco, Duaklir, Tudorza) alongside the acquired AMAG products.

Differentiator

Problem solved

Functional benefit

Products and services

• Feraheme Intravenous iron replacement product (ferumoxytol injection) for the treatment of iron deficiency anemia in adults, particularly those with chronic kidney disease or inadequate response to oral iron therapy.
• Alvesco A respiratory medication (ciclesonide) for the treatment of asthma in patients with chronic respiratory conditions.
• Duaklir A respiratory therapy product for patients with chronic respiratory conditions such as COPD.
• Tudorza A respiratory medication (aclidinium bromide) indicated for the long-term maintenance treatment of bronchospasm associated with COPD.
• Omnaris A nasal spray corticosteroid (ciclesonide) used for the treatment of nasal symptoms associated with allergic rhinitis.
• Zetonna A nasal aerosol (ciclesonide) for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves8 records

Expansion highlights3 records

Others

• Azurity Pharmaceuticals: Current ultimate parent of AMAG (via Covis); a specialty pharma platform focused on differentiated therapeutics for underserved conditions, comparable in go-to-market model.

Broad incumbents

• Novartis: Diversified pharma with broad women's health and specialty hematology adjacencies that compete for prescriber share and specialty pharmacy access.
• Sanofi: Large incumbent pharma with broader hematology, women's health, and specialty care assets whose diversification competes for the same specialty prescriber budgets as AMAG.
• AstraZeneca: Owns the broader respiratory franchise (including medicines Covis acquired from AZ in 2022); relevant as a comparable respiratory specialty incumbent in the same channel as Covis/AMAG.
• Takeda Pharmaceutical: Major specialty-care pharma with established women's health and hematology adjacencies, competing for the same specialty channel infrastructure AMAG uses.

Direct peers

• Ferring Pharmaceuticals: Specialty pharma with a focused maternal health and women's health portfolio directly mirroring AMAG's historical emphasis on maternal and reproductive care.
• American Regent: US specialty injectable company marketing Injectafer and a portfolio of hematology/iron products; directly overlaps with AMAG's hospital-channel IDA franchise.
• CSL Vifor (Vifor Pharma): Global leader in iron deficiency therapies (Ferinject/Injectafer, Venofer, Feraccru), directly competing with AMAG's Feraheme in the IV iron market across hospital and CKD channels.
• Daiichi Sankyo (Injectafer US via American Regent): Through American Regent, markets Injectafer (ferric carboxymaltose), the principal head-to-head competitor to Feraheme in the US IV iron segment.

Emerging players

• Pharmacosmos: Monofer (iron isomaltoside) is a high-dose, rapid-infusion IV iron competing with Feraheme in Europe and select international markets, increasingly relevant globally.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/amag-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMAG Pharmaceuticals